Intravenous alteplase for ischaemic stroke

Lancet

Volumn 369, Issue 9558, 2007, Pages 249-250

  Albers, Gregory W ^a   Olivot, Jean Marc ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; PLACEBO;

ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG SAFETY; FIBRINOLYTIC THERAPY; HEALTH CENTER; HUMAN; PRIORITY JOURNAL; STROKE PATIENT;

EID: 33846389938     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)60120-2     Document Type: Note

References (14)

1. Wahlgren N., Ahmed N., Davalos A., et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 369 (2007) 275-282
2. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333 (1995) 1581-1587
3. Albers G., Bates V., Clark W., Bell R., Verro P., and Hamilton S. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA 283 (2000) 1145-1150
4. Hill M., and Buchan A. Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study. CMAJ 172 (2005) 1307-1312
5. Hacke W., Donnan G., Fieschi C., et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 363 (2004) 768-774
6. Fiorelli M., Bastianello S., von Kummer R., et al. Hemorrhagic transformation within 36 hours of a cerebral infarct: relationships with early clinical deterioration and 3-month outcome in the European Cooperative Acute Stroke Study I (ECASS I) cohort. Stroke 30 (1999) 2280-2284
7. Tanne D., Bates V., Verro P., and the t-PA Stroke Survey Group. Initial clinical experience with IV tissue plasminogen activator for acute ischemic stroke: a multicenter survey. Neurology 53 (1999) 424-427
8. Katzan I., Furlan A., Lloyd L., et al. Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. JAMA 283 (2000) 1151-1158
9. Dzialowski I., Pexman J., Barber P., Demchuk A., Buchan A., and Hill M. Asymptomatic hemorrhage after thrombolysis may not be benign: prognosis by hemorrhage type in the Canadian alteplase for stroke effectiveness study registry. Stroke 38 (2007) 75-79
10. Tanne D., Gorman M., Bates V., et al. Intravenous tissue plasminogen activator for acute ischemic stroke in patients aged 80 years and older: the tPA stroke survey experience. Stroke 31 (2000) 370-375
11. Engelter S., Reichhart M., Sekoranja L., et al. Thrombolysis in stroke patients aged 80 years and older: Swiss survey of IV thrombolysis. Neurology 65 (2005) 1795-1798
12. Berrouschot J., Rother J., Glahn J., Kucinski T., Fiehler J., and Thomalla G. Outcome and severe hemorrhagic complications of intravenous thrombolysis with tissue plasminogen activator in very old (> or =80 years) stroke patients. Stroke 36 (2005) 2421-2425
13. Sylaja P., Cote R., Buchan A., and Hill M. Thrombolysis in patients older than 80 years with acute ischaemic stroke: Canadian Alteplase for Stroke Effectiveness Study. J Neurol Neurosurg Psychiatry 77 (2006) 826-829
14. The NINDS t-PA Stroke Study Group. Generalized efficacy of t-PA for acute stroke. Subgroup analysis of the NINDS t-PA Stroke Trial. Stroke 28 (1997) 2119-2125